Gilead Sciences (NQ:GILD)

Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals ↗

Topics Regulatory Compliance

P/E Ratio Insights for Gilead Sciences ↗

February 27, 2026

Via Benzinga

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 27, 2026

Via Chartmill

February 13, 2026

Via Chartmill

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

February 27, 2026

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Kymera (KYMR) Q4 2025 Earnings Call Transcript

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

Topics Earnings

February 26, 2026

Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir...

Arcus (RCUS) Q4 2025 Earnings Call Transcript

Topics Intellectual Property

Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

Topics Earnings

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics Intellectual Property

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Topics Intellectual Property

February 25, 2026

From Gilead Sciences, Inc.

Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash.

Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗

February 25, 2026

Via Benzinga

Is Amgen Stock Outperforming the Dow?

February 25, 2026

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

February 24, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Gilead Sciences to Present at Upcoming Investor Conferences

February 23, 2026

From Gilead Sciences, Inc.

Gilead Sciences is buying Arcellx for $7.8 billion because it sees potential for more than $6 billion in sales for anito-cel by 2029. GILD stock slipped as ACLX soared.

Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗

February 23, 2026

Via Investor's Business Daily

Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗

February 23, 2026

Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.

Via Benzinga

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Via Stocktwits

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

Where Gilead Sciences Stands With Analysts ↗

February 20, 2026

Via Benzinga

Peering Into Gilead Sciences Inc's Recent Short Interest ↗

February 19, 2026

Via Benzinga

February 17, 2026

From Gilead Sciences, Inc.

Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures....

5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

February 17, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Topics Earnings

3 Hyped Up Stocks We Steer Clear Of

February 15, 2026

Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Topics Economy

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Topics Artificial Intelligence ETFs Government

3 Overrated Stocks That Concern Us

February 12, 2026